Search for new lung cancer biomarkers using 13C-labeled glucose

Development of a new cancer diagnostic method based on metabolites derived from samples before and after oral administration of 13C-labeled glucose in patients with PET-positive lung cancer : Single-arm, exploratory clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051200038

Enrollment

Registered

2020-07-30

Start date

2020-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable primary lung cancer primary lung cancer

Interventions

Administration of 13C glucose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who are at least 20 years old and under 80 years old at the time of obtaining consent (2) PET-positive primary lung cancer patients who can be surgically resected (3) Patients who have given their informed consent to participate in this clinical study

Exclusion criteria

Exclusion criteria: (1) Patients with other cancers (2) Other patients judged inappropriate by the person in charge of this clinical study

Design outcomes

Primary

Measure	Time frame
Identification of derived metabolites in blood and urine after 13C glucose administration	—

Secondary

Measure	Time frame
Whether or not adverse events have occurred	—

Contacts

Public ContactMasaru Yoshida

Kobe University Hospital

myoshida@med.kobe-u.ac.jp+81-78-382-6305

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026